JP2003501457A5 - - Google Patents

Download PDF

Info

Publication number
JP2003501457A5
JP2003501457A5 JP2001502812A JP2001502812A JP2003501457A5 JP 2003501457 A5 JP2003501457 A5 JP 2003501457A5 JP 2001502812 A JP2001502812 A JP 2001502812A JP 2001502812 A JP2001502812 A JP 2001502812A JP 2003501457 A5 JP2003501457 A5 JP 2003501457A5
Authority
JP
Japan
Prior art keywords
matrix
lipophilic
active ingredient
composition according
amphiphilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001502812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501457A (ja
JP4790950B2 (ja
Filing date
Publication date
Priority claimed from IT1999MI001317A external-priority patent/ITMI991317A1/it
Priority claimed from IT2000MI000422A external-priority patent/IT1317871B1/it
Application filed filed Critical
Priority claimed from PCT/EP2000/005356 external-priority patent/WO2000076478A1/en
Publication of JP2003501457A publication Critical patent/JP2003501457A/ja
Publication of JP2003501457A5 publication Critical patent/JP2003501457A5/ja
Application granted granted Critical
Publication of JP4790950B2 publication Critical patent/JP4790950B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001502812A 1999-06-14 2000-06-09 制御放出および味感遮蔽経口医薬組成物 Expired - Lifetime JP4790950B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IT1999MI001317A ITMI991317A1 (it) 1999-06-14 1999-06-14 Sistemi terapeutici a rilascio modificato per forma farmaceutiche orali
ITMI99A001317 1999-06-14
IT99A001317 1999-06-14
IT2000MI000422A IT1317871B1 (it) 2000-03-03 2000-03-03 Sistemi terapeutici per forme farmaceutiche orali di principi attiviaventi sfavorevoli caratteristiche organolettiche.
IT2000A000422 2000-03-03
ITMI2000A000422 2000-03-03
PCT/EP2000/005356 WO2000076478A1 (en) 1999-06-14 2000-06-09 Controlled release and taste masking oral pharmaceutical compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011000091A Division JP5279850B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物
JP2011000092A Division JP5279851B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物

Publications (3)

Publication Number Publication Date
JP2003501457A JP2003501457A (ja) 2003-01-14
JP2003501457A5 true JP2003501457A5 (enExample) 2011-07-28
JP4790950B2 JP4790950B2 (ja) 2011-10-12

Family

ID=26331662

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001502812A Expired - Lifetime JP4790950B2 (ja) 1999-06-14 2000-06-09 制御放出および味感遮蔽経口医薬組成物
JP2011000092A Expired - Lifetime JP5279851B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物
JP2011000091A Expired - Lifetime JP5279850B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011000092A Expired - Lifetime JP5279851B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物
JP2011000091A Expired - Lifetime JP5279850B2 (ja) 1999-06-14 2011-01-04 制御放出および味感遮蔽経口医薬組成物

Country Status (17)

Country Link
US (20) US7431943B1 (enExample)
EP (1) EP1183014B1 (enExample)
JP (3) JP4790950B2 (enExample)
CN (1) CN1173695C (enExample)
AT (1) ATE251449T1 (enExample)
AU (1) AU5680100A (enExample)
CA (1) CA2377301C (enExample)
DE (1) DE60005819T2 (enExample)
DK (1) DK1183014T3 (enExample)
ES (1) ES2208349T3 (enExample)
HK (1) HK1046244B (enExample)
MX (1) MXPA01012889A (enExample)
NO (1) NO331642B1 (enExample)
PT (1) PT1183014E (enExample)
RU (1) RU2246293C2 (enExample)
TR (1) TR200200562T2 (enExample)
WO (1) WO2000076478A1 (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
DK1183014T3 (da) 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2005009432A1 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited New dosage regimen in case of concurrent intake of gabapentin with food and an increased oral bioavailability therewith
JP4814636B2 (ja) * 2004-01-29 2011-11-16 大日本住友製薬株式会社 ビグアナイド系薬物の内服製剤
ITMI20040187A1 (it) * 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ES2288117B1 (es) * 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
AU2007275660B2 (en) 2006-07-19 2012-08-02 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
KR20090086060A (ko) * 2006-09-12 2009-08-10 코스모 테크놀러지스 리미티드 단백질의 경구 또는 직장 투여를 위한 약학적 조성물
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
DE102007041588A1 (de) * 2007-09-01 2009-03-05 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit Hefe
WO2009133128A1 (en) * 2008-04-29 2009-11-05 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
JP2012501967A (ja) * 2008-08-20 2012-01-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 調節放出型多粒子のホットメルト押出成形
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
US20220054406A1 (en) * 2009-01-12 2022-02-24 Biokier, Inc. Composition and method for treatment of diabetes
US8470885B2 (en) 2009-01-12 2013-06-25 Biokier, Inc. Composition and method for treatment of diabetes
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US8945616B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
DE102009012788A1 (de) * 2009-03-13 2010-09-30 J. Rettenmaier & Söhne Gmbh + Co. Kg Verpressbares Tablettenmaterial mit ölhaltigem Wirkstoff, Tablette sowie Verfahren und Vorrichtung zu deren Herstellung
CN105213318A (zh) 2009-05-18 2016-01-06 希格默伊德药业有限公司 包含油滴的组合物
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2496217B1 (en) * 2009-08-24 2019-03-27 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Direct compression tablets of otilonium
MX2012003459A (es) 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
CN103429739B (zh) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 制备产生和分泌胰岛素的肠内分泌细胞的方法
WO2011154975A2 (en) 2010-06-08 2011-12-15 Cadila Healthcare Limited Pharmaceutical compositions of metformin
EP2616051A1 (en) 2010-07-29 2013-07-24 Cosmo Technologies Ltd. Pharmaceutical and/or dietary compositions based on short chain fatty acids
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
EP2446877A1 (en) * 2010-10-29 2012-05-02 Roquette Frères Modified starch derivative-based matrix for colon targeting
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
JP2014513125A (ja) 2011-05-02 2014-05-29 バイオキアー・インコーポレイテッド 糖尿病の治療用組成物および方法
AT511581A1 (de) * 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
AU2012345726B2 (en) * 2011-12-02 2017-04-13 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
IN2014DN06662A (enExample) 2012-02-13 2015-05-22 Cosmo Technologies Ltd
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
EP2722058A1 (en) 2012-10-19 2014-04-23 Cosmo Technologies Ltd Solid oral composition containing dyes for use in endoscopic diagnosis
SG11201505245XA (en) * 2013-01-14 2015-08-28 Infirst Healthcare Ltd Compositions and methods for treating severe pain
PL3795141T3 (pl) * 2013-01-14 2025-11-12 Infirst Healthcare Limited Kompozycje w postaci roztworu stałego
BR112015015870B1 (pt) * 2013-02-04 2022-09-27 Infirst Healthcare Limited Uso de uma composição farmacêutica
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
US9240075B2 (en) 2013-03-15 2016-01-19 Daqri, Llc Campaign optimization for experience content dataset
CN103417507B (zh) * 2013-08-23 2015-12-02 王显著 布地奈德药物组合物
US20150073057A1 (en) 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
ITMI20131578A1 (it) * 2013-09-25 2015-03-26 Giellepi S P A Sostanza e formulazione per il trattamento delle malattie infiammatorie croniche intestinali
IN2013MU03373A (enExample) * 2013-10-25 2015-07-17 Cadila Healthcare Ltd
WO2015071812A1 (en) 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
GB2525227B (en) 2014-04-16 2016-09-14 Jaguar Land Rover Ltd Bumper assembly method and apparatus
WO2015200901A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
EP3006453A1 (en) * 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
CN104523717A (zh) * 2015-01-06 2015-04-22 西南大学 西甲硅油奥替溴铵咀嚼片及其制备方法
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2018096161A1 (en) 2016-11-28 2018-05-31 Cosmo Technologies Ltd. Solid oral composition containing dyes
WO2018129079A1 (en) * 2017-01-03 2018-07-12 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine
CA3073195A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
EP4438039A3 (en) 2017-11-10 2024-12-04 Cosmo Technologies Ltd. Oral rifamycin sv compositions
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法
WO2022254456A1 (en) * 2021-06-01 2022-12-08 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133863A (en) 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3800051A (en) 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3586600T2 (de) 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
US4608248A (en) 1985-11-08 1986-08-26 Warner-Lambert Company Process for time-controlled release of active ingredients
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL92343A0 (en) 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP3011752B2 (ja) * 1990-10-23 2000-02-21 フロイント産業株式会社 徐放性製剤およびその製造方法
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
WO1992016214A1 (en) 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
EP0587744B1 (en) * 1991-05-28 2003-07-16 McNEIL-PPC, Inc. Chewable drug-delivery composition
US5534501A (en) * 1991-06-04 1996-07-09 A Et S Biovecteurs Particle for use as a milk fat globule substitute, composition containing same and process for the preparation of said particle
IT1250654B (it) 1991-07-08 1995-04-21 Farcon Ag Metodo per la preparazione di forme farmaceutiche orali a rilascio prolungato contenenti sostanze attive a solubilita' dipendente dal valore di ph.
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
WO1995016451A1 (fr) 1992-06-22 1995-06-22 Franck Arno Gouchet Comprimes a liberation controlee de 4-asa
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
WO1994015947A1 (en) * 1993-01-08 1994-07-21 Astra Aktiebolag Novel colon- or ileum-specific steroid derivatives
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
WO1995026715A2 (en) * 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
JP3867171B2 (ja) 1994-04-22 2007-01-10 アステラス製薬株式会社 結腸特異的薬物放出システム
US5747491A (en) * 1994-05-05 1998-05-05 Merck Sharp & Dohme Ltd. Morpholine derivatives and their use as antagonists of tachikinins
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
KR20000029784A (ko) 1996-08-02 2000-05-25 나까도미 히로다카 경구제제용캡슐과경구캡슐제제
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ES2203963T3 (es) 1997-05-30 2004-04-16 Osmotica Corp. Dispositivo osmotico multicapa.
NZ503086A (en) 1997-08-29 2002-03-01 Upjohn Co An orally administrable pharmaceutical composition comprising an inner core and two outer layers, which render it substantially free of unpleasant tastes
DE29717252U1 (de) 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
ATE314092T1 (de) * 1997-09-26 2006-01-15 Noven Pharma Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
US5965167A (en) * 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6239120B1 (en) * 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
CA2274943A1 (en) 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
DE19849737A1 (de) 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
DK1183014T3 (da) * 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
US6363635B1 (en) 1999-10-22 2002-04-02 Superior Bronze Corporation Of America Memorial markers and method for producing the same
JP4159217B2 (ja) 1999-12-15 2008-10-01 花王株式会社 皮膚外用剤
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
US20060188563A1 (en) 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
US7715806B2 (en) 2004-10-06 2010-05-11 Broadcom Corporation Method and system for diversity processing including using dedicated pilot method for closed loop
WO2008033124A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
JP5132416B2 (ja) 2008-05-08 2013-01-30 キヤノン株式会社 画像処理装置およびその制御方法
EP2151235B1 (de) 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
IT1398643B1 (it) 2010-03-04 2013-03-08 Cosmo Technologies Ltd Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
US8787888B2 (en) * 2012-08-29 2014-07-22 Facebook, Inc. Sharing location information during a communication session

Similar Documents

Publication Publication Date Title
JP2003501457A5 (enExample)
JP4790950B2 (ja) 制御放出および味感遮蔽経口医薬組成物
RU2002100367A (ru) Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
ES2337547T3 (es) Composiciones de liberacion controlada que contienen nimesulida.
CA2082944C (en) Pharmaceutical compositions
JP3305315B2 (ja) 動物及び人間の疼痛及び／又は炎症の抑制時における薬剤ならびにその製造及びその使用
US20030199481A1 (en) Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils
JP2004534057A5 (enExample)
JP2005515964A5 (enExample)
KR20080033354A (ko) 카르비도파 및 레보도파를 함유하는 고형의 연장 방출약학적 조성물
US20180071221A1 (en) Immediate release soluble ibuprofen compositions
JPH08208520A (ja) 経口薬剤構成物
ES2312652T3 (es) Composiciones farmaceuticas para la administracion oral de heparina o derivados de la misma.
US20040204403A1 (en) Pharmaceutical composition comprising ibuprofen and prochlorperazine
AU2002356421A1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
WO2003032896A2 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
RU2195935C2 (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
KR101113005B1 (ko) 비-스테로이드계 항염증성 약물 투여법
CA2946158C (en) Pharmaceutical composition with anti-inflammatory agents and production process
JPH0256328B2 (enExample)
WO2006056144A2 (es) Dispositivo osmótico que contiene licofelone
WO2002069936A2 (en) Pharmaceutical composition of ibuprofen
JP2008150298A (ja) 溶解性を改善したジフェンヒドラミン含有医薬組成物
JPH02191228A (ja) 鎮痛剤